Revolution Medicines began shipping daraxonrasib to physicians and patients under an FDA-authorized early access program for pancreatic cancer. The company said patients have been seeking access since results were reported in mid-April, when the Phase 3 trial showed near-doubling of overall survival versus standard chemotherapy. In parallel at ASCO, Replimune announced it has aligned with the FDA to resubmit its melanoma BLA for RP-1 after two prior rejections, positioning the therapy for an “urgent” review on resubmission. The combined moves highlight how late-stage wins are quickly translated into expanded pathways, while regulators still gatekeep evidence quality for approval.